Contact
For business, media, or testing-related inquiries, please get in touch.
ELEVATE INDUSTRY HEALTH & SAFETY STANDARDS WITH C-POLAR™ REVOLUTIONARY PROTECTION AGAINST VIRUSES, MICROORGANISMS, AND POLLENS
REVOLUTIONARY PROTECTION AGAINST VIRUSES, BACTERIA, MOLDS, FUNGI, AND POLLENS
* Based on third-party studies, internal testing, and data from commercial installations
Dr. Michael Mansour, Associate Professor of Medicine at Harvard Medical School, was featured on Canada's CTV News. He discussed technologies like C-POLAR™, which protect against the next pandemic.
Read more
Dr. Michael Mansour featured on CTV News
Media interview
A century ago, a well-ventilated building was considered good medicine. But by the time Covid-19 arrived, our buildings could barely breathe. How do we let the fresh air back in?
Read more
The New War on Bad Air (Article by The New York Times)
Recommended article
C-POLAR was featured on Global News. Senior Director of National Sales, Sam Chung, and Dr. Alan Rabinowitz of St. Paul's Hospital delved into our revolutionary technology.
Read more
C-POLAR featured on Global News with Sonia Sunger
Media interview
This partnership will create infection-resilient environments as C-POLAR captures, inactivates, and eradicates up to 99.99% of viruses, bacteria, molds, and fungi.
Read more
C-POLAR signs cooperation agreement with Northumbria NHS
Press release
Our Chief Science Officer Jeanne Moldenhauer, Co-Chief Innovation Officer Aldrin Or, and Senior Vice President Jackson Tse were published in March's American Pharmaceutical Review.
Read more
C-POLAR team published in The American Pharmaceutical Review
Feature
C-POLAR Ireland is strategically located within the Northumbria Healthcare NHS Manufacturing & Innovation Hub in Northumbria, UK.
Read more
C-POLAR establishes Ireland subsidiary to spearhead EU expansion
News
The study showed C-POLAR™ treated filtration material inactivated 99.4% of pseudo-type SARS CoV-2 and also increased the filtration efficiency of the filtration media from 74.2% to 97.2%.
Read more
Peer-reviewed study confirms effectiveness of C-POLAR filter media
Validation
Who We Are
C-POLAR Technologies, Inc. provides bioprotection solutions.
Studies show our patent-pending technology,
C-POLAR™, captures up to 99.99% of viruses, bacteria, molds, fungi, and pollens.*
We create infection-resilient environments, setting the global standard for health and safety for governments, private enterprises, hospitals, and schools.
*Based on third-party studies, internal testing, and data from commercial installations
Trusted By Global Organizations
NHS
The National Health Service (NHS) is the United Kingdom's publicly-funded healthcare system.
JONES LANG LASALLE
Jones Lang LaSalle is one of the largest property developers globally.
MIAMI INTERNATIONAL AIRPORT
Miami International Airport is one of the largest airports in North America.
THE GRAND HYATT HK
The Grand Hyatt HK is a five-star, luxury hotel with branches across the world.
HANG LUNG PROPERTIES
Hang Lung Properties is a leading property developer in Hong Kong and Mainland China.
AFL-CIO, METAL TRADES
The Metal Trades Department is part of the AFL-CIO, the largest federation of US unions.
Proven Effective Against
COVID
19
Staphylococcus aureus
Escherichia
coli
Pseudomonas aeruginosa
Coxsackievirus B6
MECHANISM OF ACTION
C-POLAR™ is created using a WHO and UN FAO approved food-additive. Using our patent-pending, proprietary methodology, we apply C-POLAR™ onto selected materials, imbuing them with a stable positive charge. Multiple studies have shown that C-POLAR™ treated materials effectively capture viruses, microorganisms, and pollens with high efficiency.
Our Advantages
C-POLAR™ is based on fundamental physics. Studies show C-POLAR™ can capture up to 99.99% of viruses, microorganisms, and pollens.
- Highly-Effective Against Viruses, Microorganisms, and Pollens
- Versatile Application
- Economical
- Safe For Human Use
Quote from Dr. MICHAEL K. Mansour
